<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324544</url>
  </required_header>
  <id_info>
    <org_study_id>BUP3030</org_study_id>
    <secondary_id>2010-021955-14</secondary_id>
    <nct_id>NCT01324544</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain</brief_title>
  <official_title>A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Aged From Birth to 6 Years of Age (Inclusive) Who Require Opioid Analgesia for Acute Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, pharmacokinetics (PK), and efficacy
      of intravenous (IV) buprenorphine in pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study of the PK, safety, and efficacy of IV buprenorphine in acute moderate to severe pain
      in male and female pediatric patients aged from birth to 6 years, inclusive, requiring
      continuous opioid analgesic treatment for at least 24 hours and up to 72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to change in development plan.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measures are clearance (CL/F) and apparent central volume of distribution (Vc/F) estimated using standard population nonlinear mixed effects methodology.</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participants with adverse events as a measure of safety.</measure>
    <time_frame>Up to 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Other Acute Postoperative Pain</condition>
  <condition>Prolonged Endotracheal Intubation</condition>
  <arm_group>
    <arm_group_label>Buprenorphine IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine IV</intervention_name>
    <description>Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.</description>
    <arm_group_label>Buprenorphine IV</arm_group_label>
    <other_name>Buprenex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          -  Must have written informed consent provided by the parent or legal guardian and/or
             patient assent, when appropriate

          -  Male and female children, from birth to aged 6 years, inclusive, with minimum weight
             of 2.5 kg

          -  Have or are anticipated to have acute moderate to severe pain; requiring treatment
             with an intravenous (IV) opioid analgesic medication for at least 24 hours
             postoperatively or; due to prolonged endotracheal intubation requiring IV opioid
             analgesic treatment for at least 24 hours poststabilization

          -  Must have stable vital signs

          -  Must have stable respiratory status

          -  Must be inpatient for the treatment period of the study

        Exclusion Criteria include:

          -  Have any known allergy or sensitivity to buprenorphine or other opioids (this
             criterion does not include patients who have experienced common opioid side effects
             [eg, nausea, constipation])

          -  Have evidence of impaired renal function

          -  Have hepatic impairment

          -  Have history of seizures

          -  Have a history of sleep apnea within the past year

          -  Have structural heart disease or a pacemaker

          -  Have clinically unstable cardiac disease

          -  Have used any investigational medication/therapy within 30 days prior to the first
             dose of study drug

          -  Are deemed to be unsuitable by the investigator for reason(s) not specifically stated
             in the exclusion criteria.

        Other protocol-specific inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Pain</keyword>
  <keyword>Opioid</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

